Add BrightSurf on Google Email

New research confirms HPV vaccination prevents cervical cancer

Two new Cochrane reviews show that HPV vaccines are effective in preventing cervical cancer and pre-cancerous changes, especially when given to young people before they are exposed to the virus. Girls vaccinated before the age of 16 were found to be 80% less likely to develop cervical cancer.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateNov 23, 2025

ACP encourages all adults to receive the 2025-2026 influenza vaccine

The American College of Physicians (ACP) has issued new influenza vaccine practice points that recommend standard-dose trivalent or quadrivalent vaccines for healthy adults aged 18-64, and high-dose trivalent or quadrivalent vaccines for those 65 years old. The guidelines aim to prevent seasonal epidemics caused by highly infectious fl...

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeNews article·DateNov 17, 2025

Study in Europe: monoclonal antibodies effectively prevent respiratory syncytial virus in infants

A European study found that long-acting monoclonal antibody immunisation effectively prevented hospitalisation due to RSV infection among children under two years old. The overall immunisation effectiveness was 79%, with a decline in protection over time, highlighting the need for ongoing monitoring.

SourceEuropean Centre for Disease Prevention and Control (ECDC)·JournalEurosurveillance·TypeData/statistical analysis·DateNov 13, 2025

Measles immunity 90% in BC’s Lower Mainland

A recent study found that 90% of people in BC's Lower Mainland have detectable antibodies against measles, indicating high vaccine coverage and population protection. However, the study also found lower immunity rates among older adults, with only 75% of those aged 20-39 having measurable antibodies.

SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·TypeObservational study·DateOct 14, 2025

National Association of School Nurses reaffirms strong support for school immunization requirements

The National Association of School Nurses reaffirms its commitment to school immunization requirements, citing the life-saving role of vaccines. The updated position statement recommends eliminating vaccine exemptions except in medical contraindications, emphasizing the importance of timely and complete vaccinations.

SourceSAGE·JournalThe Journal of School Nursing·TypeCommentary/editorial·DateOct 10, 2025

Drop in childhood vaccination coverage: Dutch study identifies trends driven by socioeconomic factors

A Dutch study found that vaccination coverage among children declined faster in households with lower income and those not attending daycare. The study, which analyzed over 2 million children, identified sociodemographic factors contributing to the decline, including parental education and migration background.

SourceEuropean Centre for Disease Prevention and Control (ECDC)·JournalEurosurveillance·TypeData/statistical analysis·DateOct 9, 2025

American College of Cardiology issues vaccine guidance for adults with heart disease

The American College of Cardiology recommends flu, COVID-19, RSV vaccinations and others for adults with heart disease to reduce risks of infection, hospitalization, and death. Vaccination has been shown to be highly effective in reducing these risks, yet only 30% of primary care physicians assess patients' vaccination status.

SourceAmerican College of Cardiology·JournalJournal of the American College of Cardiology·DateAug 26, 2025

Cost-effectiveness of 2023-2024 COVID-19 vaccination in US adults

A modeling study finds that COVID-19 vaccination is more cost-effective for individuals aged 65 and above, with favorable results across different parameter input scenarios. The study's findings support the Advisory Committee on Immunization Practices' decision to recommend vaccination with the 2023-2024 mRNA vaccines.

SourceJAMA Network·JournalJAMA Network Open·DateAug 7, 2025

Can African countries meet 2030 childhood immunization goals?

Despite improvements in childhood immunization coverage, many African countries are unlikely to meet global targets by 2030. The study found that socioeconomic inequalities persist in coverage, with significant gaps between wealth quintiles.

SourcePLOS·JournalPLOS Medicine·TypeComputational simulation/modeling·DateJul 29, 2025

Engineering antibodies with a novel fusion protein

Scientists at Sanford Burnham Prebys developed a new method of generating antibodies by fusing two immune system proteins, enabling the creation of stable monoclonal antibodies. This breakthrough has potential applications in diagnosing and monitoring diseases such as lupus and cancers.

SourceSanford Burnham Prebys·JournalJournal of Immunology·TypeExperimental study·DateMar 25, 2025

Controlling respiratory syncytial virus: real life data from Luxembourg

Early data from Luxembourg's national immunisation campaign against severe respiratory syncytial virus (RSV) in 2023 showed a decline in hospitalisations, especially among infants under six months old. The authors attributed this to the administration of a monoclonal antibody, nirsevimab, shortly after birth. Additionally, the mean age...

SourceEuropean Centre for Disease Prevention and Control (ECDC)·JournalEurosurveillance·TypeData/statistical analysis·DateJan 29, 2024

CHOP researchers identify molecules that optimize immune presentation of antigens across the human population

CHOP researchers have identified variants of a chaperone molecule that can enhance the loading of peptides across different HLA types, which could be used in cell therapy and immunization applications. The study found that chicken-derived TAPBPR proteins can react with multiple HLA allotypes and stabilize the empty MHC-I groove, boosti...

SourceChildren's Hospital of Philadelphia·JournalScience Advances·DateFeb 24, 2023

New research shows no link between COVID-19 vaccination during pregnancy and higher risk of preterm birth or stillbirth

A population-based retrospective cohort study found that COVID-19 vaccination during pregnancy is not associated with an increased risk of preterm birth, small for gestational age at birth, or stillbirth. The study concluded that COVID-19 vaccination during pregnancy can inform evidence-based decision-making about its safety.

SourceUniversity of Ottawa·JournalThe BMJ·TypeData/statistical analysis·DateAug 29, 2022

Study preserves memory in mice, offering promising new basis for active immunization against Alzheimer's disease

Researchers at the University of Kansas have discovered a promising new basis for active immunization against Alzheimer's disease. By injecting a recombinant methionine-rich protein into mice with the disease, they were able to improve short-term memory and learning abilities by up to 50%. The treatment also showed potential in reducin...

SourceUniversity of Kansas·JournalAntioxidants·DateMay 3, 2022

Alpaca nanobodies potently neutralize SARS-CoV-2 variants

Researchers at Karolinska Institutet in Sweden have developed a novel strategy to identify potent miniature antibodies, so-called nanobodies, against emerging SARS-CoV-2 variants. The approach led to the discovery of multiple nanobodies that effectively blocked infection with different SARS-CoV-2 variants.

SourceKarolinska Institutet·JournalScience Advances·TypeExperimental study·DateMar 25, 2022

Study shows maternal immunization against respiratory syncytial virus (RSV) would lower antimicrobial prescribing among infants

A study found that maternal immunization against respiratory syncytial virus (RSV) can reduce antimicrobial prescribing among young infants. The research, based on a blinded, multi-country trial, showed that infants of mothers assigned the RSV F vaccine experienced fewer antimicrobial prescription courses over the first 90 days of life.

SourceCenter for Disease Dynamics, Economics & Policy·JournalProceedings of the National Academy of Sciences·DateMar 14, 2022

First potential immunization against RSV for healthy infants found highly effective in phase 3 trial

A single dose of nirsevimab protected healthy infants from medically attended lower respiratory tract infections caused by RSV with 74.5% efficacy. This breakthrough results suggest a broad immunization approach is needed to mitigate the global burden of RSV on infants and healthcare services.

SourceAnn & Robert H. Lurie Children's Hospital of Chicago·JournalNew England Journal of Medicine·DateMar 2, 2022